Cargando…
Cystatin C proteoforms in chronic kidney disease
Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891521/ https://www.ncbi.nlm.nih.gov/pubmed/36724153 http://dx.doi.org/10.1371/journal.pone.0269436 |
_version_ | 1784881150097883136 |
---|---|
author | Dahl, Helene Meyer, Klaus Sandnes, Kristina Welland, Natasha Lervaag Arnesen, Iselin Marti, Hans-Peter Dierkes, Jutta Lysne, Vegard |
author_facet | Dahl, Helene Meyer, Klaus Sandnes, Kristina Welland, Natasha Lervaag Arnesen, Iselin Marti, Hans-Peter Dierkes, Jutta Lysne, Vegard |
author_sort | Dahl, Helene |
collection | PubMed |
description | Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been discovered, including an intact protein with a hydroxylated proline at the N-terminus, and N-terminal truncated forms. There is little knowledge about the biological significance of these proteoforms. Methods: Cross-sectional study of patients with different stages of chronic renal disease (pre-dialysis n = 53; hemodialysis n = 51, renal transplant n = 53). Measurement of cystatin C proteoforms by MALDI-TOF MS, assessment of medicine prescription using the first two levels of the Anatomical Therapeutic chemical system from patients’ records. Results: Patients receiving hemodialysis had the highest cystatin C concentrations, followed by pre-dialysis patients and patients with a renal transplant. In all groups, the most common proteoforms were native cystatin C and CysC 3Pro-OH while the truncated forms made up 28%. The distribution of the different proteoforms was largely independent of renal function and total cystatin C. However, the use of corticosteroids (ATC-L02) and immunosuppressants (ATC-H04) considerably impacted the distribution of proteoforms. Conclusion: The different proteoforms of cystatin C increased proportionally with total cystatin C in patients with chronic kidney disease. Prescription of corticosteroids and immunosuppressants had a significant effect on the distribution of proteoforms. The biological significance of these proteoforms remains to be determined. |
format | Online Article Text |
id | pubmed-9891521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-98915212023-02-02 Cystatin C proteoforms in chronic kidney disease Dahl, Helene Meyer, Klaus Sandnes, Kristina Welland, Natasha Lervaag Arnesen, Iselin Marti, Hans-Peter Dierkes, Jutta Lysne, Vegard PLoS One Research Article Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been discovered, including an intact protein with a hydroxylated proline at the N-terminus, and N-terminal truncated forms. There is little knowledge about the biological significance of these proteoforms. Methods: Cross-sectional study of patients with different stages of chronic renal disease (pre-dialysis n = 53; hemodialysis n = 51, renal transplant n = 53). Measurement of cystatin C proteoforms by MALDI-TOF MS, assessment of medicine prescription using the first two levels of the Anatomical Therapeutic chemical system from patients’ records. Results: Patients receiving hemodialysis had the highest cystatin C concentrations, followed by pre-dialysis patients and patients with a renal transplant. In all groups, the most common proteoforms were native cystatin C and CysC 3Pro-OH while the truncated forms made up 28%. The distribution of the different proteoforms was largely independent of renal function and total cystatin C. However, the use of corticosteroids (ATC-L02) and immunosuppressants (ATC-H04) considerably impacted the distribution of proteoforms. Conclusion: The different proteoforms of cystatin C increased proportionally with total cystatin C in patients with chronic kidney disease. Prescription of corticosteroids and immunosuppressants had a significant effect on the distribution of proteoforms. The biological significance of these proteoforms remains to be determined. Public Library of Science 2023-02-01 /pmc/articles/PMC9891521/ /pubmed/36724153 http://dx.doi.org/10.1371/journal.pone.0269436 Text en © 2023 Dahl et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Dahl, Helene Meyer, Klaus Sandnes, Kristina Welland, Natasha Lervaag Arnesen, Iselin Marti, Hans-Peter Dierkes, Jutta Lysne, Vegard Cystatin C proteoforms in chronic kidney disease |
title | Cystatin C proteoforms in chronic kidney disease |
title_full | Cystatin C proteoforms in chronic kidney disease |
title_fullStr | Cystatin C proteoforms in chronic kidney disease |
title_full_unstemmed | Cystatin C proteoforms in chronic kidney disease |
title_short | Cystatin C proteoforms in chronic kidney disease |
title_sort | cystatin c proteoforms in chronic kidney disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891521/ https://www.ncbi.nlm.nih.gov/pubmed/36724153 http://dx.doi.org/10.1371/journal.pone.0269436 |
work_keys_str_mv | AT dahlhelene cystatincproteoformsinchronickidneydisease AT meyerklaus cystatincproteoformsinchronickidneydisease AT sandneskristina cystatincproteoformsinchronickidneydisease AT wellandnatashalervaag cystatincproteoformsinchronickidneydisease AT arneseniselin cystatincproteoformsinchronickidneydisease AT martihanspeter cystatincproteoformsinchronickidneydisease AT dierkesjutta cystatincproteoformsinchronickidneydisease AT lysnevegard cystatincproteoformsinchronickidneydisease |